MoonLake falls on wider loss than previous quarter

MoonLake Immunotherapeutics

20/03/2023 18:21

** Shares of Swiss biotech firm MoonLake Immunotherapeutics
 MLTX.O  down 18.1% at $18.95 
    ** Reports loss of $0.31 per share in Q4 2022 vs loss of
$0.27 per share in Q3 2022
    ** Expects readouts for major trials in 2023  
    ** Says "strong balance sheet providing a cash runway into
2H 2024 and at least 12 months beyond expected key readouts"
    ** 
    ** MLTX rose 6.17% in 2022; started trading on Nasdaq on
April 6, after closing SPAC deal with Helix Acquisition Corp

 (Reporting By Akshita Toshniwal)
 ((Akshita.Toshniwal@thomsonreuters.com))